Topical Androgen Receptor Blocker Achieves 10.65 Hairs/cm² Density Increase Over Placebo in Pivotal Phase 3 Trial
A Local Anti-Androgen Shield Completes its Final Human Trials: In March and June 2026, researchers released highly anticipated Phase 3 results for a novel topical treatment called KX-826 (Pyrilutamide). This represents a major milestone because it is a “first-in-class” therapy designed to block hair-loss hormones directly on the scalp without affecting the rest of the body’s hormone levels. Having successfully met its primary endpoints in a pivotal late-stage trial, this treatment is now moving toward official regulatory submission, promising a highly effective, non-systemic alternative to traditional hair loss medications.
